HR and invasive breast carcinoma: This real-world study evaluated the impact of NACT on overall survival (OS) and disease-free survival (DFS), specifically focusing on differential benefits within Luminal B and high-risk Luminal B subgroups.<h4>Methods</h4>We retrospectively analyzed 990 patients with HR+/HER2- invasive breast cancer treated between 2013 and 2022.